DiviTum® results in blockbuster drug study presented at AACR
Uppsala, Sweden, April 3 2017. The latest data of the DiviTum® assay as an efficacy marker of CDK4/6 inhibition was presented in an oral session by Dr. Geoffrey Shapiro, Dana-Farber Cancer Institute, at the 2017 American Association for Cancer Research (AACR) Annual Meeting.
The results, presented as part of an ongoing clinical trial (NCT02022982) at the Dana-Farber Cancer Institute, demonstrate that the DiviTum® assay for determining Thymidine Kinase Activity (TKA) can be a practical, non-invasive tool for monitoring the efficacy of CDK4/6 inhibitors. There is a great need for a method that provides information about treatment efficacy for these novel therapies in order to optimize patient outcome and health economy. The data presented strengthen the fact that DiviTum® has the potential to become such a method.
The clinical data include DiviTum® analysis of the first 20 patients with solid tumors. DiviTum® was used to measure levels of TKA in blood samples collected before and during treatment with palbociclib (Ibrance®, Pfizer) in combination with a MEK-inhibitor. Changes in TKA measured by DiviTum® significantly reflected mode of action response to palbociclib.
During the AACR Meeting Biovica presented an abstract on DiviTum® analysis of TKA and TK release in response to palbociclib in cellular extracts, tissue culture media and mice models together with the Dana-Farber Cancer Institute and the Karolinska Institute. The abstract supports DiviTum® as a practical, non-invasive tool for monitoring the efficacy of CDK4/6 inhibitors in both preclinical models and patients.
“The resultsprovideguidanceforusing DiviTum as a test to gain early informationontheresponse to palbociclib. We look forward to includingmore patients in the study and providingmore evidence for DiviTum as anoninvasiveassay for patients treated with CDK4/6 inhibitors”, says Dr Geoffrey Shapiro, MD, PhD, Director, Early Drug Development Center at the Dana-Farber Cancer Institute.
“These results, adding to the results presented at SABCS in December 2016, furthers strengthens the evidence that DiviTum® can indicate response to CDK4/6 treatments. Now there is evidence from cell lines, animal models, patients with breast cancer and other solid tumors including lung cancer. Going forward, we’ll continue building solid evidence of the value DiviTum® can bring to patients and health care providers.”, says Anders Rylander, CEO Biovica.
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
The _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.
This cookie is installed by Google Analytics.
A variation of the _gat cookie set by Google Analytics and Google Tag Manager to allow website owners to track visitor behaviour and measure site performance. The pattern element in the name contains the unique identity number of the account or website it relates to.
Installed by Google Analytics, _gid cookie stores information on how visitors use a website, while also creating an analytics report of the website's performance. Some of the data that are collected include the number of visitors, their source, and the pages they visit anonymously.
Hotjar sets this cookie to detect the first pageview session of a user. This is a True/False flag set by the cookie.
Hotjar sets this cookie to identify a new user’s first session. It stores a true/false value, indicating whether it was the first time Hotjar saw this user.
Hotjar sets this cookie to know whether a user is included in the data sampling defined by the site's pageview limit.
Hotjar sets this cookie to know whether a user is included in the data sampling defined by the site's daily session limit.